This is what they want!
Shake. Shake. Shake.
Shake. Shake. Shake.
Shake those shares.
Dun. Dun. Dun. Dun.
Whoever the board put in charge of negotiating the debt deals sucks and would get pigeon holed in a traditional middle eastern market, although the intentions were right. Fact. Not really familiar with Adam, but I can already tell he's a douche spinner. Fact. MMs, shorters, and other big players and artificially deflating PPS. Fact.
Bio T-Gel revenue is not why this stock should be worth more than $1.20 easily. It really only benefits the company in spirit, restoring some much needed stret cred, putting money into the research pot with the upfront payment. Whatever revenue it actually generates is a m00t point and quite frankly, icing on the cake. Libigel is still the main focus, and I won't bother to go over why, because nutsyprofessor has done an excellent job of that. Quite frankly, even without Libigel, Biosante has the pill plus, the cancer vaccines, and is paying off debts and adding to the cash flow.
